Projects

prof. RNDr. Silvia Pastoreková, DrSc.
Director General

International

Current
  • Alliance4Life Bridging the Research and Innovation Gap in Life Sciences
    Program: Horizon Europe
    Duration: 1. 3. 2024 – 29. 2. 2028
  • Role of the CA IX ectodomain in tumor growth and metastasis
    Program: Other
    Duration: 11. 11. 2014 – 31. 12. 2025
Finished
  • VACCELERATE - European Corona Vaccine Trial Accelerator Platform
    Program: Horizon 2020
    Duration: 28. 1. 2021 – 27. 1. 2025
  • Alliance for Life Sciences: From Strategies to Actions in Central and Eastern Europe
    Program: Horizon 2020
    Duration: 1. 5. 2021 – 30. 4. 2024
  • INNOVATIVE PARTNERSHIP FOR ACTION AGAINST CANCER
    Program: Other
    Duration: 1. 4. 2018 – 31. 12. 2021
  • Life Science Alliance: Closing Research and Innovation Divide in the EU
    Program: Horizon 2020
    Duration: 1. 1. 2018 – 31. 12. 2019
  • Association of the hypoxia-induced carbonic anhydrase IX with drug response, miRNA profile and oncogenic pathways: from integrative analysis of the NCI60 cancer cell panel to cancer patients
    Program: JRP
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Building-up Centre of Excellence for advanced materials application
    Program: Horizon 2020
    Duration: 1. 6. 2015 – 31. 5. 2016
  • Biomedical engineering for cancer and brain disease diagnosis and therapy development
    Program: FP7
    Duration: 1. 4. 2011 – 31. 3. 2015
  • Biomarkers for Early Detection and Therapy of Adrenal Gland Tumors: Molecular Pathogenesis and Clinical Correlates
    Program: SRDA
    Duration: 1. 1. 2009 – 31. 12. 2014
  • Metastatic tumours facilitated by hypoxic tumour microenvironments
    Program: FP7
    Duration: 1. 2. 2009 – 31. 1. 2014
  • Hypoxia sensing, signalling and adaptation
    Program: COST
    Duration: 16. 11. 2009 – 15. 11. 2013
  • On-chip cell handling and analysis
    Program: FP6
    Duration: 1. 4. 2007 – 31. 12. 2011
  • Analysis of the therapeutic anti-CA IX antibody
    Program: Bilateral - other
    Duration: 1. 1. 2009 – 31. 12. 2009
  • Targeting newly discovered oxygen-sensing cascades for novel cancer treatments. Biology, equipment, drug candidates
    Program: FP6
    Duration: 1. 2. 2004 – 28. 2. 2009
  • Development of new inhibitors of carbonic anhydrase IX with possible pharmacological applications in the therapy of cancer
    Program: Inter-academic agreement
    Duration: 1. 1. 2004 – 31. 12. 2006

National

Current
  • Characterization of the soluble form of carbonic anhydrase IX in molecular subtypes of breast cancer and its significance for prognosis.
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • Study of inverse relationship between carbonic anhydrases CA IX and CA IV and its significance for tumor phenotype
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2027
  • „Matching" grants to resources obtained from the private sector in the framework of research cooperation
    Program:
    Duration: 6. 8. 2024 – 30. 6. 2026
  • „Matching" grants to resources obtained from the private sector in the framework of research cooperation
    Program:
    Duration: 13. 6. 2024 – 30. 6. 2026
Finished
  • Systemic public research institution - biobank for cancer and rare diseases
    Program:
    Duration: 1. 1. 2024 – 31. 12. 2024
  • Cell-in-cell phenomena as microevolutionary processes in cancer progression: a role for hypoxia-induced carbonic anhydrase IX
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 6. 2024
  • Carbonic anhydrase IX: one of the key components of exosomes secreted from cancer cells
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Unraveling the mechanisms linking obesity and cancer progression: the interplay between adipocytes and cancer cells
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Long-term strategic research of prevention, intervention and mechanisms of obesity and its comorbidities
    Program:
    Duration: 1. 9. 2019 – 30. 6. 2023
  • Strengthening of research, development and innovation capacities of translational biomedical research of human diseases
    Program:
    Duration: 1. 1. 2020 – 30. 6. 2023
  • Study of pro-metastatic functions of carbonic anhydrase IX, relationship between CA IX and mucins and hypoxic microenvironment in pancreatic cancer.
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Large-capacity cleaning of airborne pathogens
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Immune response to SARS-CoV-2 infection and development of clinically relevant virological tests to improve the management of the COVID-19 pandemic
    Program: SRDA
    Duration: 16. 9. 2020 – 31. 12. 2021
  • Research of humanized antibodies in targeted treatment of hypoxic tumors
    Program: Other projects
    Duration: 1. 12. 2018 – 1. 12. 2021
  • The role of CA IX in adaptation to tumor microenvironment and in resistance to anticancer therapy: molecular mechanisms and clinical implications
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Interaction of hypoxia with the signaling pathways implicated in differentiation, tumor progression and metastasis.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Soluble and/or exosome-associated Carbonic anhydrase IX as a biologically active molecule.
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • -
    Program:
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Graphene - based nanoplatform for detection of cancer
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • Elucidation of novel pro-metastatic functions of tumor-associated carbonic anhydrase IX and its cross-talk with pro-inflammatory response
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 6. 2019
  • The role of carbonic anhydrase IX in tumor metabolism: regulation, function and clinical significance
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Carbonic anhydrase IX as a functional component of cancer progression: the role in epithelial-mesenchymal transition and intercellular signaling
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Regulation of carbonic anhydrase IX release and biological role of shed ectodomain in tumor cell-cell interactions
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • Study of molecular mechanisms of carbonic anhydrase IX regulation and significance of its expression in colorectal cancer.
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • -
    Program: EU Structural Funds Research & Development
    Duration: 1. 10. 2011 – 31. 10. 2015
  • Center of excellence for the study of metabolic aspects of development, diagnostics and treatment of cancer diseases
    Program:
    Duration: 1. 7. 2011 – 31. 12. 2014
  • The role of carbonic anhydrase IX in cell migration as a part of metastatic cascade.
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 12. 2014
  • Identification of the molecular pathways driven by hypoxia-induced carbonic anhydrase IX in tumor cells
    Program: SRDA
    Duration: 1. 5. 2011 – 31. 10. 2014
  • Centre of Excellence for Translational Research in Molecular medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 31. 5. 2012
  • Improvement of Centre of Excelence for the Use of Informational Biomacromolecules in Prevention of Diseases and for Improvement of the Quality of Life
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2010 – 30. 4. 2012
  • Biological properties and immunotherapeutic potential of the monoclonal antibodies specific for the tumor-associated protein CA IX
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Centre of Excelence for the Use of Informational Biomacromolecules in Prevention of Diseases and for Improvement of the Quality of Life
    Program: EU Structural Funds Research & Development
    Duration: 1. 7. 2009 – 30. 6. 2011
  • Center of Excelence for Translational Research in Molecular Medicine
    Program: EU Structural Funds Research & Development
    Duration: 1. 6. 2009 – 31. 5. 2011
  • -
    Program: SRDA
    Duration: 1. 4. 2007 – 31. 3. 2011
  • Centre of Excellence in Cardiovascular Research
    Program:
    Duration: 1. 1. 2007 – 31. 1. 2010
  • Production of liquid live vaccine agaist rubeola
    Program: Other projects
    Duration: 1. 4. 2008 – 31. 12. 2009
  • (Role of the carbonic anhydrase IX in the bicarbonate transport metabolon formed in hypoxic cells and its implications for cancer physiology
    Program: SRDA
    Duration: 1. 5. 2006 – 30. 6. 2009
  • Epithelial-mesenchymal transition in the model of breast carcinoma stem cells in vitro
    Program: SRDA
    Duration: 1. 3. 2006 – 1. 3. 2009
  • Targeting newly discovered oxygen-sensing cascades for novel cancer treatments. Biology, equipment, drug candidates
    Program:
    Duration: 1. 2. 2004 – 31. 1. 2009
  • Extracelular form of hypoxia - induced tumor - associated carbonic adhydrase IX /CA IX/: molecular mechanisms of shedding and biological significance in oncogenesis
    Program: VEGA
    Duration: 1. 1. 2006 – 31. 12. 2008
  • Interplay between lymphocytic choriomeningitis virus and cellular proteins during the persistent infection
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Mutual relationship between hypoxia and oncogenic DNA viruses and its effects on the expression of viral and cellular genes
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees